Nisoldipine, (±)3-isobutyl-5-methyl-1,4-dihydro-2,6-dimethyl-4-(2′-nitrophenyl)pyridine-3,5-dicarboxylate, is a second generation of dihydropyridine calcium antagonist which has a selective arteriolar vasodilation but shows negligible effects on the other vessels and myocardium. 1 In previous reports, nisoldipine in human plasma has been mainly determined using liquid or gas chromatography with mass spectrometry, following a liquid-liquid extraction. [2] [3] [4] Since the sample clean-up procedure is the time-consuming, and the rate-limiting step in the quantification of analytes in matrices, researchers are trying to simplify the step using a protein precipitation frequently used for fast sample pretreatment and disrupting protein-drug binding. On the other hand, the ionization suppressive effect of endogenous materials in plasma, even after the protein precipitation, is the most common reason for assay failure in LC/MS/MS.
we develop a simple, sensitive and accurate method for determining nisoldipine in human plasma using liquid chromatography with tandem mass spectrometry following a simple protein precipitation with a mixture of an organic solvent and a metal ionic solution. This method was successfully applied to characterize the pharmacokinetics of nisoldipine in humans.
Experimental

Reagents and chemicals
Nisoldipine and felodipine were kindly donated by Hanlim Pharmaceutical Co. Ltd. (Seoul, South Korea). HPLC-grade organic solvents and zinc sulfate were purchased from Merck Co. (Darmstadt, Germany) and Sigma Chemical Co. (St. Louis, MO, USA), respectively. All the other chemicals and solvents were of the highest analytical grade available.
Preparation of standards and quality controls
Nisoldipine and felodipine (internal standard, IS) were separately dissolved in methanol at 1 mg/ml. The standard solutions were serially diluted with methanol and added as drug-free plasma to obtain the concentrations of 0.1, 0.5, 1, 2.5, 5 and 10 ng/ml for nisoldipine. IS was diluted with a mixture of methanol and 10% of zinc sulfate aqueous solution (4:1, v/v) at 10 ng/ml. Calibration graphs in plasma were derived from the peak area ratio of nisoldipine to IS with a linear regression.
Quality controls were prepared daily in 180 μl of blank human plasma by adding 20 μl of standard solution to evaluate the inter-and intra-day precision and accuracy of this assay method.
Characterization of the product ions using tandem mass spectrometry
One micromolar nisoldipine and IS solutions were infused into the mass spectrometer separately at a flow rate of 10 μl/min to characterize the product ions of each compound. The precursor ions, [M+H] + , and the pattern of fragmentation were monitored using positive ion mode. The major peaks observed in the MS/MS scan were used to quantify nisoldipine and IS.
Analytical system
The concentrations of nisoldipine in human plasma were quantified using liquid chromatography-mass spectrometry with a PE SCIEX API 4000 LC/MS/MS system (Applied Biosystems, Foster City, CA, USA) equipped with an electrospray ionization interface used to generate positive ions [M+H] + . The compounds were separated on a reversed-phase column (Xterra C18, 2.1 × 50 mm, 3.5 μm particle size; Waters, Milford, MA, USA) with an isocratic mobile phase consisting of methanol and 0.1% formic acid buffer (75:25 (v/v)). The mobile phase was eluted using a HP 1100 series pump (Agilent, Wilmington, DE, USA) at 0.3 ml/min.
The turboion spray interface was operated in the positive ion mode at 5500 V and 400˚C. The operating conditions were optimized by flow injection of a mixture of all analytes, and were as follows: nebulizing gas flow, 1.04 L/min; auxiliary gas flow, 4.0 L/min; curtain gas flow, 1.44 L/min; orifice voltage, 80 V; ring voltage, 400 V; collision gas (nitrogen) pressure, 3.58 × 10 -5 torr. Quantitation was performed by multiple reaction monitoring (MRM) of the protonated precursor ion and the related product ion for nisoldipine using the internal standard method with peak area ratio. The mass transitions used for nisoldipine and IS were m/z 389.1 → 357.0 (declustering potential, 70 eV; collision energy, 27 eV; dwell time, 300 ms) and 384.0 → 338.1 (declustering potential, 40 eV; collision energy, 13 eV; dwell time, 300 ms), respectively. A simple and rapid quantification method was developed for determining nisoldipine in plasma. After a simple protein precipitation with a mixture of 10% of zinc sulfate and methanol, the analytes were chromatographed on a reversed-phase C18 column, and detected by MS/MS. The assay precision was less than 10.7%, and the accuracy ranged from 86 to 112%. The limit of quantification was 0.1 ng/ml. This method was used to measure the plasma concentration of nisoldipine from healthy subjects after a single 5-mg oral dose of nisoldipine. 
Sample preparation
Two-hundred microliters of internal standard (10 ng/ml) were added to 0.2 ml of plasma, followed by 10 s of vigorous vortexmixing. The mixture was centrifuged at 13200 rpm for 10 min. Ten microliters of the supernatant were injected onto the analytical column.
Validation procedure
The validation parameters were selectivity, extraction recovery, precision, and accuracy. Five batches of blank heparinized human plasma were screened to determine the specificity. The extraction recovery of nisoldipine was calculated by comparing the peak area ratio measured for the standard solution with that obtained for plasma extracts after the extraction procedure. The precision and accuracy of the intra-and inter-day assay validation were estimated using the inverse prediction of the concentration of the quality controls from the calibration curves.
Clinical application
Twenty healthy subjects who gave written informed consent took part in this study. Health problems, drug or alcohol abuse, and abnormalities in laboratory screening values were exclusion criteria. This study was approved by the Institutional Review Board of Gachon Gil Hospital (Incheon, Korea). After an overnight fast, all the subjects were given a single 5-mg oral dose of nisoldipine sustained-released tablet. Blood samples (6 ml) were taken before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 24 and 48 h after drug administration and stored at -80˚C until analysis.
Results and Discussion
Mass spectra
Precursor ions for nisoldipine and felodipine, and their corresponding product ions were determined from spectra obtained during the infusion of standard solutions into a mass spectrometer using an electrospray ionization source, which was operated in positive ionization mode with collision nitrogen gas in Q2 of MS/MS system. Nisoldipine and felodipine mainly produced protonated molecules at m/z 388.9 and 384.2, respectively. Their product ions proposed were scanned in Q3 after collision with nitrogen in Q2 at m/z 356.9 for nisoldipine, and at m/z 338.3 for felodipine. 6 These are the most sensitive product ions for quantification (Fig. 1) .
Determination of nisoldipine
There were no interfering peaks at the elution times for either analyte (nisoldipine, 1.3 min) or IS (felodipine, 1.6 min). Figure 2 represents the chromatograms for blank plasma (A), blank plasma with IS (B), the limit of quantification (C) and a representative plasma sample equivalent to 0.7 ng/ml for nisoldipine from a volunteer (D).
While a liquid-liquid extraction method was used for the purification of nisoldipine from plasma in the previous study: nisoldipine was extracted with ethyl acetate following alkalinization, 2 we employed a simple protein precipitation with a mixture of methanol and zinc sulfate solution. At the very beginning, methanol or acetonitrile were only used for the precipitation. 7 However, the limit of detection (5 ng/ml) was not low enough to detect nisoldipine in human plasma after a single oral administration of 5 mg nisoldipine.
Polson et al. reported the protein precipitation efficiencies of acids (10% trichloroacetic acid, 5% m-phosphoric acid), metal ion (10% zinc sulfate heptahydrate), and organic solvents (acetonitrile, methanol, ethanol) in mouse, rat, dog and human plasma. 5 For human plasma, zinc sulfate solution was the most efficient to precipitate the protein (≈96.8%), when an equivalent volume was added to the plasma. After we took of this point, a couple of combination mixtures, i.e., 10% of zinc sulfate solution was mixed up with methanol at 10, 20 and 50%, were checked at different volumes (200, 400 and 600 μl; data not shown), and finally an equivalent volume of the mixture of 20% of zinc sulfate solution in methanol was added to 0.2 ml of human plasma.
The limit of quantification came to 0.1 ng/ml at a signal-to-noise (S/N) ratio of 5. The present method saves lots of time for the pretreatment of human plasma. Such a low limit of quantification might be attributed to the more efficient clean-up process of plasma protein by co-use of zinc sulfate with methanol compared with use of only an organic solvent, which seemed to improve the ionization and detection of nisoldipine in human plasma.
Robustness, linearity, precision and accuracy
The robustness of this method using the present analytical 1598 ANALYTICAL SCIENCES DECEMBER 2006, VOL. 22 instrument was checked by a measurement repeated five times of both drugs (10 ng/ml for nisoldipine and 50 ng/ml for felodipine) at the same well and 6 different wells: the coefficients of variation of the precision were found to be less than 3 and 5% for nisoldipine and felodipine, respectively. The calibration curves in plasma provided a reliable response from 0.5 to 20 ng/ml for nisoldipine. The mean equations of the regression lines in plasma was y = (0.354 ± 0.005)x -(0.004 ± 0.001) (r 2 > 0.9999). The intra-and inter-day precision and accuracy of our method are listed in Table 1 . The coefficients of variation of the precision of the intra-and inter-day validation were less than 10.7 and 9.8%, respectively. The accuracy of the method ranged within 92.7 -112.2% for intraday assays, and within 85.5 -104.2% for inter-day assays.
Clinical application
Time profiles of plasma nisoldipine-concentration after an oral administration of 5 mg nisoldipine sustained released formulation are illustrated in Fig. 3 , and the pharmacokinetic parameters are listed in Table 2 .
In conclusion, our LC/MS/MS method is a very simple, sensitive, and accurate way to determine nisoldipine in plasma, and is suitable for the human pharmacokinetic studies of nisolipine. 1599 ANALYTICAL SCIENCES DECEMBER 2006, VOL. 22 Fig. 2 Chromatograms of nisoldipine and felodipine. A, Blank plasma; B, plasma spiked with 10 ng/ml of internal standard; C, limit of quantification; D, plasma sample equivalent to 0.7 ng/ml for nisoldipine from a volunteer 5 h after the oral dose of 5 mg nisoldipine. Table 1 109.5 ± 6.6 (6.0) 98.6 ± 9.6 (9.8) 2
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